Quality of life improves with alemtuzumab over 6 years even in patients with relapsing-remitting multiple sclerosis who developed thyroid adverse events
2020 ◽
2009 ◽
Vol 41
(6)
◽
pp. 322-328
◽
2016 ◽
Vol 5
(3)
◽
pp. 181
◽
2007 ◽
Vol 13
(6)
◽
pp. 783-791
◽